The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ELCC 2023 | Managing low-grade immunotherapy-associated toxicity in lung cancer
Milica Kontic Jovanovic, MD, PhD, Clinical Center of Serbia, Belgrade, Serbia, discusses how certain relative contraindications have shifted to absolute contraindications for immunotherapy treatment as our knowledge of immunotherapy-associated toxicity has progressed. Dr Jovanovic also comments on the common line of practice following immunotherapy-associated toxicity, which is the discontinuation of immunotherapy or administration of glucocorticoids. This interview took place at the European Lung Cancer Congress 2023 in Copenhagen, Denmark.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
